Interpreting registry-derived drug studies: Does societal context matter?

Arthritis and Rheumatism

Volumn 60, Issue 11, 2009, Pages 3155-3157

  Kremer, Joel M ^a   Greenberg, Jeffrey ^b  

^a Center for Rheumatology LLP   (United States)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

CANCER REGISTRY; CANCER RISK; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG RESEARCH; DRUG SAFETY; EDITORIAL; ELECTRONIC MEDICAL RECORD; HEALTH CARE SYSTEM; HOSPITALIZATION; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SKIN CANCER; SWEDEN; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HEMATOLOGIC NEOPLASMS; HUMANS; METHOTREXATE; REGISTRIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SINGLE-PAYER SYSTEM; SKIN NEOPLASMS; SOCIOECONOMIC FACTORS; SWEDEN; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 70350528801     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24880     Document Type: Editorial

References (10)

1. Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor α therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009;60:3180-3189
2. Greenberg JD, Kishimoto M, Strand V, Cohen S, Olenginski T, Harrington T, et al. Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort. Am J Med 2008;121:532-538 (Pubitemid 351694340)
3. Hyrich KL, Watson KD, Symmons DP, Silman AJ. Predictors of response to etanercept and infliximab among patients with rheumatoid arthritis. Ann Rheum Dis 2005;64 Suppl 3:1398.
4. Kremer JM, Gibofsky A, Greenberg JD. The role of drug and disease registries in rheumatic disease epidemiology. Curr Opin Rheumatol 2008;20:123-130 (Pubitemid 351339882)
5. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
6. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-2285 (Pubitemid 43736578)
7. Dixon W, Silman A. Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the metaanalysis by Bongartz et al. Arthritis Res Ther 2006;8:111. (Pubitemid 44712076)
8. Stern R, Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 2004;31:1538-1545 (Pubitemid 39006634)
9. Dixon WG, Watson K, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, et al, on behalf of the British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-2376
10. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova- Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-3412 (Pubitemid 41612206)